Bill Hennessy with CEO and Founder, Dr. Greg Piefer, testifying before the Nuclear Regulatory Commission at SHINE’s mandatory hearing in December 2015

NRC Issues SHINE Construction Permit

Press Releases

NRC Issues SHINE Construction Permit

February 25, 2016 – Monona, WI – SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements, announced today that the U.S. Nuclear Regulatory Commission (NRC) has authorized the issuance of the SHINE construction permit.  SHINE is the only U.S. medical isotope producer to have reached this stage of the NRC permitting process since the 1960s.

The issuance of the construction permit is the culmination of more than four years of effort by both SHINE and the NRC.  It follows two years of environmental data collection and safety analysis by SHINE, as well as two years of rigorous safety and environmental reviews by the NRC.

With the construction permit in hand, SHINE has federal regulatory approval to begin construction of its approximately 57,000 ft2 medical isotope manufacturing facility in Janesville, WI.

“This is the first time in over fifty years a medical isotope plant of this kind has been granted a construction permit,” said Greg Piefer, CEO of SHINE.  “We’ve developed a greener, safer, and cheaper way to produce these life-saving isotopes on a global scale.  Once operational we expect the Janesville facility will improve the lives of over 1 billion people over its lifetime.  It’s a very exciting time at SHINE.”
“SHINE diligently followed the clear regulatory path provided by the NRC, resulting in the regulatory clearance to build our facility in Janesville,” said Jim Costedio, Vice President of Regulatory Affairs and Quality.

SHINE’s work is supported by the Department of Energy’s National Nuclear Security Administration’s molybdenum-99 program, which seeks to develop reliable and sustainable domestic production of molybdenum-99 without the use of highly enriched uranium.

SHINE plans to hold a celebratory event in Janesville in March.

About Moly-99

Molybdenum-99 (moly-99) is a radioisotope that decays into the diagnostic imaging agent technetium-99m (tech-99m). Tech-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer.

Despite constituting approximately half of world demand for moly-99, the U.S. does not produce any moly-99 domestically and imports 100 percent of its supply from foreign nuclear reactors. The majority of these reactors are beyond their original design life and scheduled to be shut down in the coming years.  Previous outages of these aging facilities have caused major isotope shortages, significantly impacting patient care.

SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including moly‑99.

About SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!

Media Contact: